Market Place
Sourcing Support
Transgene`s viral cancer vaccine flunks midphase test
15 Oct 2024 //
FIERCE PHARMA
Transgene, NEC, and BostonGene Expand Collaboration
05 Mar 2024 //
BUSINESSWIRE
Transgene Announces Upcoming Investor Meetings
21 Dec 2023 //
BUSINESSWIRE
Transgene Strengthens its Leadership Team to Accelerate its Growth Strategy
05 Dec 2023 //
BUSINESSWIRE
Transgene Reports Business Update and Q3 2023 Financial Position
07 Nov 2023 //
BUSINESSWIRE
Transgene & BioInvent - First Patient Treated in Phase I Trial Assessing BT-001
10 Oct 2023 //
BUSINESSWIRE
Transgene Advances Its Innovative Immunotherapy Pipeline
20 Sep 2023 //
BUSINESSWIRE
Transgene Announces Upcoming Investor Meetings
14 Sep 2023 //
BUSINESSWIRE
Transgene and NEC Present New Data on TG4050
06 Jun 2023 //
BUSINESSWIRE
Transgene Presents Immunological Data Demonstrating that TG4001
05 Jun 2023 //
BUSINESSWIRE
Transgene and BioInvent report positive data for oncolytic virus
25 May 2023 //
CLINICAL TRIALS ARENA
Transgene doses first patient in oncolytic virus study
10 May 2023 //
CLINICAL TRIALS ARENA
AstraZeneca scraps Transgene pact in blow to oncolytic viruses
06 May 2023 //
FIERCE BIOTECH
Transgene Announces New Leadership Structure to Accelerate the Development
05 May 2023 //
PHARRMIWEB
Transgene, NEC present positive data from TG4050 at AACR 2023 meeting
20 Apr 2023 //
PHARMABIZ
New Data Showing that Transgene and NEC’s Individualized Cancer Vaccine TG4050
18 Apr 2023 //
BUSINESSWIRE
Transgene - Preclinical Results Showing TG6050, a Novel Oncolytic Virus
17 Apr 2023 //
BUSINESSWIRE
Transgene:Availability of Preparatory Documents for the Combined General Meeting
11 Apr 2023 //
BUSINESSWIRE
Transgene to Host KOL Webinar on TG405
04 Apr 2023 //
BUSINESSWIRE
Transgene Announces Upcoming Investor Meetings
27 Mar 2023 //
BUSINESSWIRE
Transgene: 2022 Full-year Results and Business Update
16 Mar 2023 //
BUSINESSWIRE
Transgene to Present Posters Highlighting Potential of Immunotherapy Pipeline
15 Mar 2023 //
BUSINESSWIRE
Transgene Appoints John C. Bell and Pedro Romero as Key Scientific Advisors
09 Mar 2023 //
BUSINESSWIRE
Transgene Receives Approval to Start a Phase I Trial of TG6050
06 Jan 2023 //
BUSINESSWIRE
Transgene Announces Upcoming Investor Meetings
15 Dec 2022 //
BUSINESSWIRE
Transgene and BioInvent Joint Paper on BT-001 Wins JITC Award
14 Nov 2022 //
BUSINESSWIRE
Transgene Reports Business Update And Q3 2022 Financial Position
07 Nov 2022 //
BUSINESSWIRE
Transgene Announces +ve Interim Analysis Results of PhII Trial Evaluating TG4001
02 Nov 2022 //
BUSINESSWIRE
Presentations to Highlight Transgene’s Competitive Positioning
27 Sep 2022 //
BUSINESSWIRE
Transgene Confirms the Potential of the Intravenous Route of its Invir.IO™
12 Sep 2022 //
BUSINESSWIRE
Positive Readouts for Transgene’s Clinical Stage Candidates
07 Sep 2022 //
BUSINESSWIRE
Transgene Announces Upcoming Investor Meetings
31 Aug 2022 //
BUSINESSWIRE
Transgene, BioInvent Announce Trial Collaboration and Supply Agreement with MSD
27 Jun 2022 //
BUSINESSWIRE
Transgene and BioInvent Announce Positive Progress for BT-001
27 Jun 2022 //
BUSINESSWIRE
Transgene Presented Additional Phase I Data with TG4050 at ASCO 2022
06 Jun 2022 //
BUSINESSWIRE
Transgene to Present Updated Positive Prelim Data from PI Trials with TG4050
26 May 2022 //
BUSINESSWIRE
Transgene’s Combined General Meeting of May 25, 2022
25 May 2022 //
BUSINESSWIRE
Transgene Announces Upcoming Investor Meetings
17 May 2022 //
BUSINESSWIRE
Transgene: Q1 2022 Financial Position and Business Update
10 May 2022 //
BUSINESSWIRE
Transgene to Present Prelim Phase I Data at AACR, on Potential of TG4050
08 Apr 2022 //
BUSINESSWIRE
Transgene: Availability of Preparatory Documents for Combined General Meeting
05 Apr 2022 //
BUSINESSWIRE
Transgene Empowers Board of Directors Governance; Appoints Independent Chairman
31 Mar 2022 //
BUSINESSWIRE
Transgene to Present New Positive Prelim Phase I Data on TG4050 at AACR 2022
09 Mar 2022 //
BUSINESSWIRE
Transgene Appoints Steven Bloom as Chief Business Officer
10 Feb 2022 //
BUSINESSWIRE
Transgene announces License Option Exercise by AZ for an Oncolytic Virus
14 Dec 2021 //
BUSINESSWIRE
Transgene and NEC Announce Positive Preliminary Data From Phase I TG4050 Trial
22 Nov 2021 //
BUSINESSWIRE
BioInvent and Transgene to present preclinical data on BT-001 oncolytic virus
09 Nov 2021 //
BIOINVENT
Transgene, BioInvent Present Preclinical Data of BT-001 at SITC 2021
09 Nov 2021 //
BUSINESSWIRE
Transgene and BioInvent to present oncolytic virus data at SITC 2021
05 Oct 2021 //
PHARMAFILE
Transgene Participates in New Cancer Research Consortium
01 Sep 2021 //
BUSINESSWIRE
Transgene begins patient enrollment in phase I trial of TG4050
30 Jun 2021 //
PHARMABIZ
First Head & Neck Cancer Patient Enrolled in the UK in a Trial with TG4050
28 Jun 2021 //
BUSINESSWIRE
Transgene Strengthens Global IP Protection for its Novel Invir.IO™
08 Jun 2021 //
BUSINESSWIRE
Transgene and BioInvent Receive IND Approval from the U.S. FDA for BT-001,
27 May 2021 //
BUSINESSWIRE
Transgene Reports Business Update and End Q1 2021 Financial Position
27 Apr 2021 //
BIOSPACE
Transgene Presents Initial Phase I Data of TG6002, Highlighting the Potential
09 Apr 2021 //
BIOSPACE
Transgene Presents Initial Phase I Data of TG6002, Highlighting
08 Apr 2021 //
BUSINESSWIRE
Transgene Expands Phase II Clinical Trial of Therapeutic Vaccine TG4001
10 Mar 2021 //
BUSINESSWIRE
Transgene and BioInvent enrol first subject in solid tumour trial
02 Mar 2021 //
CLINICALTRIALSARENA
Transgene and BioInvent Have Enrolled First Patient in Phase I/IIa Trial
01 Mar 2021 //
BUSINESSWIRE
